<DOC>
	<DOC>NCT01468493</DOC>
	<brief_summary>The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.</brief_summary>
	<brief_title>A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients</brief_title>
	<detailed_description />
	<mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
	<criteria>Age at entry is between 14 and 70 years biopsyproven primary FSGS proteinuria &gt;=3 g/day without corticosteroids or CsA treatment before entry Chronic Inflammatory Diseases malignant tumor diabetes mellitus contraindications for the treatment of corticosteroids or CsA treatment untolerate to or unwilling to accept corticosteroids or CsA treatment</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>FSGS</keyword>
	<keyword>suPAR</keyword>
</DOC>